GPI-anchored single chain Fv - an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike

Retrovirology

Volumn 7, Issue , 2010, Pages

  Wen, Michael ^a   Arora, Reetakshi ^b   Wang, Huiqiang ^a   Liu, Lihong ^a   Kimata, Jason T ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ADHESION; CONTROLLED STUDY; DENDRITIC CELL; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID RAFT; NONHUMAN; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS SPIKE; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; CELL CULTURE; CELL MEMBRANE; GENETIC TRANSDUCTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; GLYCOSYLPHOSPHATIDYLINOSITOLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE MICRODOMAINS; NEUTRALIZATION TESTS; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

EID: 77957300589     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-79     Document Type: Article

References (72)

1. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
2. Poignard P, Saphire EO, Parren PW, Burton DR. Biologic aspects of structural features. Annu Rev Immunol 2001, 19:253-274. gp120, 10.1146/annurev.immunol.19.1.253, 11244037.
3. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027. 10.1126/science.7973652, 7973652.
4. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF, Burton DR, Ho DD. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101-109. 188553, 7527081.
5. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647. 238102, 7692082.
6. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994, 68:4031-4034. 236911, 7514684.
7. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765. 10.1089/08892220152741450, 11788027.
8. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, Burton DR, Ho DD, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617. 189569, 7474069.
9. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108. 189917, 8551569.
10. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. 10.1126/science.1178746, 19729618.
11. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905. 10.1128/JVI.75.22.10892-10905.2001, 114669, 11602729.
12. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861. 10.1126/science.1187659, 20616233.
13. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817. 10.1126/science.1192819, 20616231.
14. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 2009, 10:573-578. 10.1038/ni.1746, 2796958, 19448659.
15. Kozak SL, Heard JM, Kabat D. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. J Virol 2002, 76:1802-1815. 10.1128/JVI.76.4.1802-1815.2002, 135872, 11799176.
16. Nguyen DH, Giri B, Collins G, Taub DD. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp Cell Res 2005, 304:559-569. 10.1016/j.yexcr.2004.11.022, 15748900.
17. Percherancier Y, Lagane B, Planchenault T, Staropoli I, Altmeyer R, Virelizier JL, Arenzana-Seisdedos F, Hoessli DC, Bachelerie F. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J Biol Chem 2003, 278:3153-3161. 10.1074/jbc.M207371200, 12431990.
18. Popik W, Alce TM, Au WC. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002, 76:4709-4722. 10.1128/JVI.76.10.4709-4722.2002, 136131, 11967288.
19. Dimitrov DS. Fusin--a place for HIV-1 and T4 cells to meet. Nat Med 1996, 2:640-641. 10.1038/nm0696-640, 8640552.
20. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999, 283:357-362. 10.1126/science.283.5400.357, 9888845.
21. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002, 99:6913-6918. 10.1073/pnas.102562599, 124503, 11997472.
22. Zhang MY, Dimitrov DS. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 2007, 13:203-212. 10.2174/138161207779313669, 17269928.
23. Lee SJ, Garza L, Yao J, Notkins AL, Zhou P. A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: a new way to fight HIV. J Immunol 2004, 173:4618-4626.
24. Lee SJ, Arora R, Bull LM, Arduino RC, Garza L, Allan J, Kimata JT, Zhou P. A nonneutralizing anti-HIV Type 1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV type 1-susceptible cells. II. Inhibition of HIV type 1 captured and transferred by DC-SIGN. AIDS Res Hum Retroviruses 2006, 22:874-883. 10.1089/aid.2006.22.874, 16989613.
25. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991, 65:4832-4838. 248941, 1714520.
26. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888. 10.1126/science.280.5371.1884, 9632381.
27. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004, 78:568-575. 10.1128/JVI.78.2.568-575.2004, 368739, 14694088.
28. Melikyan GB, Egelhofer M, von Laer D. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol 2006, 80:3249-3258. 10.1128/JVI.80.7.3249-3258.2006, 1440409, 16537592.
29. Medof ME, Nagarajan S, Tykocinski ML. Cell-surface engineering with GPI-anchored proteins. FASEB J 1996, 10:574-586.
30. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572. 10.1038/42408, 9177342.
31. Chazal N, Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 2003, 67:226-237. table of contents, 10.1128/MMBR.67.2.226-237.2003, 156468, 12794191.
32. Carter GC, Bernstone L, Sangani D, Bee JW, Harder T, James W. HIV entry in macrophages is dependent on intact lipid rafts. Virology 2009, 386:192-202. 10.1016/j.virol.2008.12.031, 19185899.
33. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001, 17:1009-1019. 10.1089/088922201300343690, 11485618.
34. de Haard JJ, Kazemier B, Oudshoorn P, Boender P, van Gemen B, Koolen MJ, van der Groen G, Hoogenboom HR, Arends JW. Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire. J Gen Virol 1998, 79(Pt 12):2883-2894.
35. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, et al. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004, 43:1410-1417. 10.1021/bi035323x, 14769016.
36. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67:3978-3988. 237765, 7685405.
37. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160:1558-1578. 10.1084/jem.160.5.1558, 2187498, 6238120.
38. Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, et al. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 2009, 27:6777-6790. 10.1016/j.vaccine.2009.08.056, 19732860.
39. Miller AD, Chen F. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 1996, 70:5564-5571. 190516, 8764070.
40. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557-10565. 10.1128/JVI.77.19.10557-10565.2003, 228502, 12970440.
41. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
42. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737. 10.1038/nature05580, 2584968, 17301785.
43. Binley JM, Ngo-Abdalla S, Moore P, Bobardt M, Chatterji U, Gallay P, Burton DR, Wilson IA, Elder JH, de Parseval A. Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. Retrovirology 2006, 3:39. 10.1186/1742-4690-3-39, 1543650, 16817962.
44. Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP. Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 1996, 70:4530-4537. 190389, 8676479.
45. Nobile C, Petit C, Moris A, Skrabal K, Abastado JP, Mammano F, Schwartz O. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol 2005, 79:5386-5399. 10.1128/JVI.79.9.5386-5399.2005, 1082762, 15827153.
46. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010, 2:36ra43.
47. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028. 10.1126/science.1118398, 2408531, 16284180.
48. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, Hevey M, Schmaljohn C, Schmaljohn A, Aman MJ. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002, 195:593-602. 10.1084/jem.20011500, 2193767, 11877482.
49. Manie SN, de Breyne S, Vincent S, Gerlier D. Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J Virol 2000, 74:305-311. 10.1128/JVI.74.1.305-311.2000, 111540, 10590118.
50. Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseudotyping. J Virol 2001, 75:7175-7183. 10.1128/JVI.75.15.7175-7183.2001, 114446, 11435598.
51. Scheiffele P, Roth MG, Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J 1997, 16:5501-5508. 10.1093/emboj/16.18.5501, 1170182, 9312009.
52. Vincent S, Gerlier D, Manie SN. Measles virus assembly within membrane rafts. J Virol 2000, 74:9911-9915. 10.1128/JVI.74.21.9911-9915.2000, 102028, 11024118.
53. Chung CS, Huang CY, Chang W. Vaccinia virus penetration requires cholesterol and results in specific viral envelope proteins associated with lipid rafts. J Virol 2005, 79:1623-1634. 10.1128/JVI.79.3.1623-1634.2005, 544138, 15650188.
54. Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect 2007, 9:96-102. 10.1016/j.micinf.2006.10.015, 17194611.
55. Funk A, Mhamdi M, Hohenberg H, Heeren J, Reimer R, Lambert C, Prange R, Sirma H. Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry. J Virol 2008, 82:10532-10542. 10.1128/JVI.00422-08, 2573206, 18768975.
56. Lu X, Silver J. Ecotropic murine leukemia virus receptor is physically associated with caveolin and membrane rafts. Virology 2000, 276:251-258. 10.1006/viro.2000.0555, 11040117.
57. Bender FC, Whitbeck JC, Ponce de Leon M, Lou H, Eisenberg RJ, Cohen GH. Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol 2003, 77:9542-9552. 10.1128/JVI.77.17.9542-9552.2003, 187402, 12915568.
58. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000, 74:8358-8367. 10.1128/JVI.74.18.8358-8367.2000, 116346, 10954535.
59. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864. 109730, 9525605.
60. Prodromou C, Pearl LH. Recursive PCR: a novel technique for total gene synthesis. Protein Eng 1992, 5:827-829. 10.1093/protein/5.8.827, 1287665.
61. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000, 25:217-222. 10.1038/76095, 10835641.
62. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 2004, 101:2706-2711. 10.1073/pnas.0308527100, 365685, 14981267.
63. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995, 69:6705-6711. 189580, 7474080.
64. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses 1996, 12:107-115. 10.1089/aid.1996.12.107, 8834460.
65. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987, 236:819-822. 10.1126/science.3646751, 3646751.
66. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol 1991, 65:3973-3985. 248827, 1830110.
67. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, Peden KW. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 1996, 12:191-194. 10.1089/aid.1996.12.191, 8835195.
68. Freed EO, Myers DJ, Risser R. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol 1989, 63:4670-4675. 251101, 2677400.
69. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007, 360:218-234. 10.1016/j.virol.2006.10.017, 1945152, 17097711.
70. Ndung'u T, Renjifo B, Essex M. Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. J Virol 2001, 75:4964-4972. 10.1128/JVI.75.11.4964-4972.2001, 114899, 11333875.
71. Zhou P, Lee J, Moore P, Brasky KM. High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. Hum Gene Ther 2001, 12:1843-1855. 10.1089/104303401753153901, 11589827.
72. Yu Kimata MT, Cella M, Biggins JE, Rorex C, White R, Hicks S, Wilson JM, Patel PG, Allan JS, Colonna M, Kimata JT. Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN. J Virol 2002, 76:11827-11836. 10.1128/JVI.76.23.11827-11836.2002, 136877, 12414925.